Trimethoprim-sulphamethoxazole in the treatment of enteric fever in the Sudan.
Patients with enteric fever confirmed by isolation of Salmonella species from blood culture, were treated with the combination of trimethoprim-sulphamethoxazole (co-trimoxazole). All 133 patients responded well to treatment. The mean defervescence was 2.74 days. No serious side effects were noticed and relapses occurred in the patients during the period of follow up.
D000293:Adolescent; D000328:Adult; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007565:Jaundice / Q000150:complications; D008288:Malaria / Q000150:complications; D008297:Male; D008875:Middle Aged; D013397:Sudan; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D013997:Time Factors; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014435:Typhoid Fever / Q000150:complications / Q000188:drug therapy*
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole